Mendrala Konrad, Czober Tomasz, Darocha Tomasz, Hudziak Damian, Podsiadło Paweł, Kosiński Sylweriusz, Jagoda Bogusz, Gocoł Radosław
Department of Anaesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland.
Department of Cardiac Surgery, Upper-Silesian Medical Centre, Medical University of Silesia, Katowice, Poland.
Perioper Med (Lond). 2024 Jun 10;13(1):54. doi: 10.1186/s13741-024-00411-w.
Due to the distinctive nature of cardiac surgery, patients suffering from hereditary spherocytosis (HS) are potentially at a high risk of perioperative complications resulting from hemolysis. Despite being the most prevalent cause of hereditary chronic hemolysis, the standards of surgical management are based solely on expert opinion.
We analyze the risk of hemolysis in HS patients after cardiac surgery based on a systematic review of the literature. We also describe a case of a patient with hereditary spherocytosis who underwent aortic valve repair.
This systematic review was registered in the PROSPERO international prospective register of systematic reviews (CRD42023417666) and included records from Embase, MEDLINE, Web of Science, and Google Scholar databases. The case study investigates a 38-year-old patient who underwent surgery for an aortic valve defect in mid-2022.
Of the 787 search results, 21 studies describing 23 cases of HS undergoing cardiac surgery were included in the final analysis. Hemolysis was diagnosed in five patients (one coronary artery bypass graft surgery, two aortic valve bioprosthesis, one ventricular septal defect closure, and one mitral valve plasty). None of the patients died in the perioperative period. Also, no significant clinical hemolysis was observed in our patient during the perioperative period.
The literature data show that hemolysis is not common in patients with HS undergoing various cardiac surgery techniques. The typical management of a patient with mild/moderate HS does not appear to increase the risk of significant clinical hemolysis. Commonly accepted beliefs about factors inducing hemolysis during cardiac surgery may not be fully justified and require further investigation.
由于心脏手术的独特性质,患有遗传性球形红细胞增多症(HS)的患者围手术期因溶血而出现并发症的风险可能很高。尽管HS是遗传性慢性溶血的最常见原因,但手术管理标准仅基于专家意见。
我们通过对文献的系统回顾,分析心脏手术后HS患者的溶血风险。我们还描述了一例接受主动脉瓣修复的遗传性球形红细胞增多症患者的病例。
本系统回顾已在国际前瞻性系统评价注册库PROSPERO(CRD42023417666)中注册,纳入了来自Embase、MEDLINE、科学网和谷歌学术数据库的记录。该病例研究调查了一名在2022年年中接受主动脉瓣缺损手术的38岁患者。
在787条检索结果中,最终分析纳入了21项描述23例接受心脏手术的HS患者的研究。5例患者被诊断为溶血(1例冠状动脉搭桥术、2例主动脉瓣生物假体置换、1例室间隔缺损修补和1例二尖瓣成形术)。所有患者均未在围手术期死亡。此外,我们的患者在围手术期未观察到明显的临床溶血。
文献数据表明,接受各种心脏手术技术的HS患者中溶血并不常见。轻度/中度HS患者的典型管理似乎不会增加明显临床溶血的风险。关于心脏手术期间诱发溶血因素的普遍观点可能没有充分的依据,需要进一步研究。